Acquisition will strengthen the mRNA-based cancer immunotherapy candidates, marking BioNTech’s milestone in its oncology strategy. Acquisition of CureVac will complement BioNTech’s capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing. All-stock acquisition has potential to create value for both companies’ shareholders given their complementary capabilities, focus on mRNA, and shared vision.

For his outstanding achievements in his doctorate at the interface between chemistry and biology, Jonas Wilhelm is awarded an Otto Hahn Medal 2025 by the Max Planck Society. He wrote his thesis in the department Chemical Biology of Kai Johnsson at the Max Planck Institute for Medical Research. In his doctorate, Jonas Wilhelm developed a molecular tool, a biosensor that records and permanently stores biological activities at the cellular level.